Galiano Gold Inc. (TSX: GAU) (NYSE American: GAU) (“Galiano” or the “Company”) is pleased to report its fourth quarter (“Q4”) ...
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
Lupoi knows the program, which helps given Cal's fiscal limitations. He also has renowned recruiting prowess on the West ...
Additionally, Jon Christensen, our President, is here to answer questions during the Q&A portion of the call. At the start of ...
Galiano Gold Inc. (TSX: GAU) (NYSE American: GAU) ("Galiano" or the "Company") is pleased to report its fourth quarter ("Q4") and ...
Selected Highlights Fourth quarter Operating EBITDA* was negative $20.1 million (net loss of $308.7 million) compared to negative $28.1 million (net loss of $80.8 million) in the third quarter of 2025 ...
The S&P/ASX 200 is set to tumble after closing just shy of fresh all-time highs on Thursday. Here are today's top stories.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results